Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients

British Journal of Clinical Pharmacology

Volumn 68, Issue 1, 2009, Pages 116-119

  Sekar, Vanitha ^a   Lefebvre, Eric ^b   Mariën, Kris ^c   De Pauw, Martine ^c   Vangeneugden, Tony ^c   Pozniak, Anton ^d   Hoetelmans, Richard M W ^c  

^a Tibotec Inc   (United States)

^b Janssen Cilag BV Netherlands   (Netherlands)

^c TIBOTEC BVBA   (Belgium)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Darunavir; Nevirapine; Pharmacokinetic interactions; Ritonavir

Indexed keywords

DARUNAVIR PLUS RITONAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; CROSS-OVER STUDIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME;

EID: 67650935285     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03430.x     Document Type: Article

References (12)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Department of Health and Human Services, November 3, 2008 1 139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (last accessed 17 April 2008).
2. Back D, Sekar V, Hoetelmans RM. Darunavir: pharmacokinetics and drug interactions. Antivir Ther 2008 13 : 1 13.
3. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008 42 : 1048 59.
4. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999 27 : 1488 95.
5. Arastéh K, Clumeck N, Pozniak A, Lazzarin A, De Meyer S, Muller H, Peeters M, Rinehart A, Lefebvre E. TMC114-C207 Study Team. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. AIDS 2005 19 : 943 7.
6. Jackson A, Boffitto M, Moyle G, Hill A, Sekar V, Lefebvre E, De Pauw M, DeMasi R, Hoetelmans R. The pharmacokinetic (PK) profile of darunavir with low-dose ritonavir (DRV/r) in various multiple-dose regimens over 120 hours. HIV Med 2008 9 : P31.
7. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wöhrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E POWER 1 and 2 Study Groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007 369 : 1169 78.
8. Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, Norris D, Lefebvre E, de Béthune MP, Tomaka F, De Pauw M, Vangeneugden T, Spinosa-Guzman S TITAN Study Group. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007 370 : 49 58.
9. Sahai J, Cameron W, Salgo M, Stewart F, Myers M, Lamson M, Gagnier P. Drug interaction study between saquinavir (SQV) and nevirapine (NVP). 4th Conference on Retroviruses and Opportunistic Infections (CROI), Washington DC, USA, 22-26 January 1997; Abstract 614.
10. Boehringer Ingelheim Pharmaceuticals Inc. Viramune® (nevirapine) US Prescribing Information, revised June 2008. Available at http://bidocs. boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase= renetnt&folderPath=/Prescribing+Information/PIs/Viramune/Viramune.pdf (last accessed 23 October 2008).
11. Abbott Laboratories Limited. Kaletra® tablets (lopinavir/ritonavir 200/50 mg) Summary of Product Characteristics, revised 7 October 2008. Available at http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documented= 18442 (last accessed 23 October 2008).
12. Sekar V, De Meyer S, Vangeneugden T, Lefebvre E, De Pauw M, Van Baelen B, De Paepe E, de Béthune M-P, Hoetelmans R, Parys W. Pharmacokinetic/ pharmacodynamic (PK/PD) analyses of TMC114 in the POWER 1 and POWER 2 trials in treatment-experienced HIV-infected patients. 13th Conference on Retroviruses and Opportunistic Infections (CROI), Denver, CO, USA, 5-9 February 2006; Abstract J-121.